[{"id":"3d25e824-c9ff-4382-955e-f2a17cda0af9","acronym":"KEYMOVE","url":"https://clinicaltrials.gov/study/NCT05976815","created_at":"2023-08-04T17:10:03.133Z","updated_at":"2024-07-02T16:35:37.851Z","phase":"","brief_title":"Improving Response to Chemotherapy by Adding Physical Exercise in the Neoadjuvant Setting of Breast Cancer Patients","source_id_and_acronym":"NCT05976815 - KEYMOVE","lead_sponsor":"University Institute of Maia","biomarkers":" CD8 • IFNG • TNFA • SPARC • CD4 • NCAM1 • DCN","pipe":"","alterations":" ","tags":["CD8 • IFNG • TNFA • SPARC • CD4 • NCAM1 • DCN"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 07/31/2023","start_date":" 07/31/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-09-07"},{"id":"68aa0036-1540-4538-858b-bf876fa2e9ec","acronym":"RACING","url":"https://clinicaltrials.gov/study/NCT03745430","created_at":"2021-01-18T18:20:40.965Z","updated_at":"2025-02-25T14:27:50.093Z","phase":"Phase 1/2","brief_title":"RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03745430 - RACING","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9","pipe":" | ","alterations":" EGFR mutation • PTEN mutation","tags":["PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 06/17/2022","primary_completion_date":" 06/17/2022","study_txt":" Completion: 04/23/2023","study_completion_date":" 04/23/2023","last_update_posted":"2023-05-24"},{"id":"c05e0fd8-f927-4e8c-a832-08281974edc0","acronym":"ABRADES","url":"https://clinicaltrials.gov/study/NCT03275818","created_at":"2021-01-18T16:10:41.239Z","updated_at":"2024-07-02T16:36:09.269Z","phase":"Phase 2","brief_title":"Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT03275818 - ABRADES","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" CTNNB1 • SPARC","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1 • SPARC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 05/09/2017","start_date":" 05/09/2017","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2022-06-07"},{"id":"f246394e-54b4-4b17-b39b-7e6c094aa722","acronym":"","url":"https://clinicaltrials.gov/study/NCT05387330","created_at":"2022-05-24T12:54:21.769Z","updated_at":"2024-07-02T16:36:10.006Z","phase":"","brief_title":"Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment","source_id_and_acronym":"NCT05387330","lead_sponsor":"Tanta University","biomarkers":" ABL1 • BCR • SPARC","pipe":"","alterations":" ","tags":["ABL1 • BCR • SPARC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 07/25/2021","primary_completion_date":" 07/25/2021","study_txt":" Completion: 12/28/2021","study_completion_date":" 12/28/2021","last_update_posted":"2022-05-24"},{"id":"1c4fa735-a3a1-4a91-b827-112dc27c4d19","acronym":"","url":"https://clinicaltrials.gov/study/NCT01566435","created_at":"2021-01-18T06:38:29.921Z","updated_at":"2025-02-25T14:33:26.041Z","phase":"Phase 2","brief_title":"Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head \u0026 Neck Cancer","source_id_and_acronym":"NCT01566435","lead_sponsor":"Washington University School of Medicine","biomarkers":" SPARC","pipe":"","alterations":" ","tags":["SPARC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • 5-fluorouracil • albumin-bound paclitaxel • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 08/09/2012","start_date":" 08/09/2012","primary_txt":" Primary completion: 10/31/2013","primary_completion_date":" 10/31/2013","study_txt":" Completion: 10/31/2019","study_completion_date":" 10/31/2019","last_update_posted":"2020-10-01"},{"id":"e8679002-e744-457b-9f56-cf59b25100b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00736944","created_at":"2021-01-18T02:46:43.165Z","updated_at":"2025-02-25T14:26:12.847Z","phase":"Phase 2","brief_title":"Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, \u0026 5-FU for Advanced Head and Neck Cancer","source_id_and_acronym":"NCT00736944","lead_sponsor":"Washington University School of Medicine","biomarkers":" SPARC","pipe":"","alterations":" ","tags":["SPARC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • 5-fluorouracil • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 12/19/2008","start_date":" 12/19/2008","primary_txt":" Primary completion: 08/31/2010","primary_completion_date":" 08/31/2010","study_txt":" Completion: 07/06/2020","study_completion_date":" 07/06/2020","last_update_posted":"2020-09-09"},{"id":"70778bc0-3e31-47c3-88bf-df60f3515bbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00733408","created_at":"2021-01-18T02:45:46.459Z","updated_at":"2024-07-02T16:37:04.898Z","phase":"Phase 2","brief_title":"Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer","source_id_and_acronym":"NCT00733408","lead_sponsor":"University of Washington","biomarkers":" EGFR • HER-2 • ER • PGR • CEACAM5 • SPARC","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • HER-2 • ER • PGR • CEACAM5 • SPARC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • erlotinib • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 04/23/2008","start_date":" 04/23/2008","primary_txt":" Primary completion: 07/05/2017","primary_completion_date":" 07/05/2017","study_txt":" Completion: 09/28/2017","study_completion_date":" 09/28/2017","last_update_posted":"2018-12-04"},{"id":"995d3419-1912-45d5-9f74-0d65886d7871","acronym":"","url":"https://clinicaltrials.gov/study/NCT00404235","created_at":"2021-01-18T01:24:52.959Z","updated_at":"2024-07-02T16:37:06.024Z","phase":"Phase 2","brief_title":"Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00404235","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" SPARC • IL2","pipe":"","alterations":" ","tags":["SPARC • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 12/01/2008","primary_completion_date":" 12/01/2008","study_txt":" Completion: 03/01/2010","study_completion_date":" 03/01/2010","last_update_posted":"2018-10-16"},{"id":"57129053-8089-4fdc-ac8c-e02c0c7b5481","acronym":"","url":"https://clinicaltrials.gov/study/NCT00503906","created_at":"2021-01-18T01:48:28.605Z","updated_at":"2024-07-02T16:37:22.513Z","phase":"Phase 2","brief_title":"Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT00503906","lead_sponsor":"University of Miami","biomarkers":" HER-2 • SPARC","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 negative","tags":["HER-2 • SPARC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • gemcitabine • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2017-05-12"}]